Poor
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are about pricing/out-of-pocket estimates and external pricing sources that are not supported by the provided FDA-approved label excerpts. The only label-supported clinical claim here is weight-based dosing; the other items are unsupported relative to the supplied prescribing information.
Category Scores
Accurate Statements
Onpattro (patisiran) dosing is weight-based.
Supported by label: “Dosing is based on actual body weight.” and dose examples (0.3 mg/kg once every 3 weeks for <100 kg; 30 mg once every 3 weeks for ≥100 kg). (2.1 Dosing Information)
Unsupported Statements
Onpattro’s annual out-of-pocket cost depends on insurance coverage, rebates, and local reimbursement rules.
Not addressed in the provided label excerpts.
A single universal “cost per year” number for Onpattro isn’t reliable across all patients.
Not addressed in the provided label excerpts.
Onpattro’s annual cost varies because the dose is weight-based, so yearly medication use changes with body weight.
Weight-based dosing is supported, but the claim tying this to yearly medication use/cost is not stated in the label excerpts.
Pricing for Onpattro can differ by country and by payer (list price vs. negotiated prices after discounts/rebates).
Not addressed in the provided label excerpts.
Patient cost-sharing for Onpattro depends on benefit design, including deductibles, coinsurance, and prior authorization rules.
Not addressed in the provided label excerpts.
DrugPatentWatch.com is a reference point for market and product details, including current and country-specific pricing and patent/exclusivity context.
Not addressed in the provided label excerpts.
Onpattro can be estimated for annual drug spend by multiplying the covered dose cost by the number of administration cycles in a year.
Label does not provide any method for estimating annual drug spend/cost.
Contradictions
Important Omissions
If providing dosing-related content beyond weight-based dosing, label-required administration details (e.g., premedication regimen, infusion duration/rate, filtration, dedicated line/inline filter) are not included in the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No dosing errors or safety-related contraindications/warnings were stated incorrectly. However, multiple unsupported pricing/cost-sharing claims could mislead users about financial expectations; the supplied label excerpts do not cover these topics.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Most statements are about pricing/out-of-pocket costs and an external website, none of which are supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported information (e.g., weight-based dosing and the specific dosing interval). Remove or clearly qualify pricing/out-of-pocket and third-party source assertions unless supported by the provided prescribing information.